Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryoko Yamada

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
Hepatology (Baltimore, Md.)|January 7, 2022
TNF receptor-related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF-κB-inducing kinase-mediated hepatocyte transdifferentiationYuto Shiode, Takahiro Kodama, Satoshi Shigeno, et al.
Hepatology Communications|May 24, 2022
Inhibition of nonhomologous end joining-mediated DNA repair enhances anti-HBV CRISPR therapyKazuhiro Murai, Takahiro Kodama, Hayato Hikita, et al.
Journal of Gastroenterology and Hepatology|April 17, 2022
Prognostic impact of worsening of esophageal varices after balloon-occluded retrograde transvenous obliterationKazuma Shinkai, Ryotaro Sakamori, Ryoko Yamada, et al.
Gastroenterology|December 21, 2020
Hepatic Stellate Cells in Hepatocellular Carcinoma Promote Tumor Growth Via Growth Differentiation Factor 15 ProductionYuta Myojin, Hayato Hikita, Masaya Sugiyama, et al.
Scientific Reports|January 24, 2020
Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathwayKazuhiro Murai, Hayato Hikita, Yugo Kai, et al.
Hepatology Communications|August 11, 2018
Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis CYuki Tahata, Ryotaro Sakamori, Ayako Urabe, et al.
Journal of Gastroenterology|May 9, 2014
The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, et al.
Cancers|February 25, 2022
Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined ImmunotherapyYuta Myojin, Takahiro Kodama, Ryotaro Sakamori, et al.
Hepatology (Baltimore, Md.)|June 9, 2021
Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver FibrosisKazuhiro Kozumi, Takahiro Kodama, Hiroki Murai, et al.
Plos One|December 21, 2022
Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosisKumiko Shirai, Hayato Hikita, Ryotaro Sakamori, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
Hepatology (Baltimore, Md.)|January 7, 2022
TNF receptor-related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF-κB-inducing kinase-mediated hepatocyte transdifferentiationYuto Shiode, Takahiro Kodama, Satoshi Shigeno, et al.
Hepatology Communications|May 24, 2022
Inhibition of nonhomologous end joining-mediated DNA repair enhances anti-HBV CRISPR therapyKazuhiro Murai, Takahiro Kodama, Hayato Hikita, et al.
Journal of Gastroenterology and Hepatology|April 17, 2022
Prognostic impact of worsening of esophageal varices after balloon-occluded retrograde transvenous obliterationKazuma Shinkai, Ryotaro Sakamori, Ryoko Yamada, et al.
Gastroenterology|December 21, 2020
Hepatic Stellate Cells in Hepatocellular Carcinoma Promote Tumor Growth Via Growth Differentiation Factor 15 ProductionYuta Myojin, Hayato Hikita, Masaya Sugiyama, et al.
Scientific Reports|January 24, 2020
Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathwayKazuhiro Murai, Hayato Hikita, Yugo Kai, et al.
Hepatology Communications|August 11, 2018
Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis CYuki Tahata, Ryotaro Sakamori, Ayako Urabe, et al.
Journal of Gastroenterology|May 9, 2014
The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, et al.
Cancers|February 25, 2022
Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined ImmunotherapyYuta Myojin, Takahiro Kodama, Ryotaro Sakamori, et al.
Hepatology (Baltimore, Md.)|June 9, 2021
Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver FibrosisKazuhiro Kozumi, Takahiro Kodama, Hiroki Murai, et al.
Plos One|December 21, 2022
Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosisKumiko Shirai, Hayato Hikita, Ryotaro Sakamori, et al.
Pageof 9